Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results

Hims & Hers reported Q1 2026 revenue of $608.1 million, up 4% year over year, with subscribers rising 9% to 2.584 million. The quarter was mixed: gross margin fell to 65% from 73% and net income swung to a $92.1 million loss, but the company raised full-year 2026 revenue guidance to $2.8 billion-$3.0 billion and EBITDA guidance to $275 million-$350 million. Management also highlighted a strategic shift in its GLP-1 offering and said the outlook excludes the pending Eucalyptus acquisition.

Analysis

The key signal is not the top-line beat; it is that management is choosing to sacrifice near-term margin for mix expansion and geographic optionality while simultaneously advertising a longer-duration growth runway. That matters because the business is increasingly behaving like a scaled consumer platform with operating leverage tied to fulfillment, diagnostics, and cross-sell, not a pure subscription replenishment model. The pivot toward branded GLP-1 access should improve conversion and reduce regulatory fragility versus a compounding-heavy mix, but it also raises the bar on inventory discipline and payer/partner stability.

The immediate losers are higher-quality gross margin assumptions and any investor base that was underwriting a clean “subscription software-like” margin expansion path. The step-up in SG&A and cost of revenue suggests the company is absorbing restructuring, legal, and acquisition integration costs now in exchange for a more durable category position later; if this works, unit economics should improve over the next 2-3 quarters, but if demand broadening stalls, these costs will look like permanent margin dilution. Competitively, the larger threat is to smaller telehealth and niche weight-loss operators that lack the balance sheet to match paid acquisition intensity or fund diagnostic infrastructure.

The market’s likely underappreciating timing asymmetry: the next 30-60 days are about whether Q2 guidance can be met without another margin leg down, while the next 6-12 months hinge on whether international expansion and the Eucalyptus deal actually add high-quality subscribers rather than just revenue. The biggest tail risk is regulatory or legal friction around the GLP-1 strategy, because that would compress both growth expectations and the multiple simultaneously. A second-order positive is that stronger cash generation plus a still-material cash pile gives them optionality to keep buying growth, which can sustain the stock even if GAAP losses remain noisy.

Key Decisions for Investors

• Maintain/enter a tactical long in HIMS into Q2 prints only on pullbacks, with a 4-8 week horizon; the setup favors upside if guidance is confirmed, but trim on any evidence that margins are not stabilizing after the strategic pivot.
• Pair trade: long HIMS / short a basket of smaller telehealth or direct-to-consumer healthcare names over 1-3 months; HIMS has the scale and balance-sheet flexibility to absorb transition costs while weaker peers are more exposed to CAC inflation and regulatory noise.
• Buy downside protection via HIMS put spreads for the next earnings cycle; the main risk is not revenue miss but a second margin reset if GLP-1 mix, legal costs, or acquisition integration prove more expensive than guided.
• If the stock rallies hard on headline growth, fade part of the move with a medium-term short against HIMS post-earnings strength; the multiple is vulnerable if investors start capitalizing one-time items as recurring operating costs.